{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-039051","form_type":"8-K","ticker":"ENTA","cik":"0001177648","company_name":"ENANTA PHARMACEUTICALS INC","filed_at":"2023-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.318705+00:00","generated_at":"2026-06-12T03:47:18.237951+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Enanta Q3 loss $1.86/diluted share; revenue $18.9M; positive Phase 1 RSV data","bullets":["Net loss $39.1M ($1.86/diluted) vs. $31.7M ($1.53) in prior-year Q3; revenue $18.9M down from $19.5M.","Cash and marketable securities $392.5M at June 30; sold 54.5% of future royalty to OMERS for $200M.","Positive Phase 1 data for RSV L-protein inhibitor EDP-323; Phase 2 human challenge study expected early Q4 2023.","Updated FY2023 guidance: R&D $165M-$175M; G&A $50M-$55M; royalty portion to OMERS from Q4 onward.","Phase 2 COVID EDP-235 showed 1.0 log viral load drop in nucleocapsid-negative patients treated within 3 days."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-039051","json":"https://secwatch.observer/filing/0000950170-23-039051.json","markdown":"https://secwatch.observer/filing/0000950170-23-039051.md","text":"https://secwatch.observer/filing/0000950170-23-039051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1177648/000095017023039051/0000950170-23-039051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1177648/000095017023039051/enta-20230807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T03:47:18.237951+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d62f4cce16fd13c6de6eeb1cdeb34d534ddd4003","claim":"ENANTA PHARMACEUTICALS INC reported fiscal third quarter ended June 30, 2023 results: revenue $18.9 million, net income Net loss for the three months ended June 30, 2023 was $39.1 million, or a loss of $1.86 per diluted common share, EPS $1.86 per diluted common share. Guidance reaffirmed.","evidence_excerpt":"Expect to Initiate Phase 2 Human Challenge Study in Early 4Q 2023. • Cash and Marketable Securities Totaled $392.5 Million at June 30, 2023 • Royalty Revenue for the Quarter was $18.9 Million WATERTOWN, Mass., Aug. 7, 2023 – Enanta Pharmaceuticals, Inc . (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1177648/000095017023039051/0000950170-23-039051-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal third quarter ended June 30, 2023"},{"label":"Revenue","value":"$18.9 million"},{"label":"Net income","value":"Net loss for the three months ended June 30, 2023 was $39.1 million, or a loss of $1.86 per diluted common share"},{"label":"EPS","value":"$1.86 per diluted common share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}